Speed it up, slow it down…An issue of bicalutamide release from 3D printed tablets.
3D printing
Bicalutamide
Co-extrusion
Controlled release
Dissolution
Tablets
Journal
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982
Informations de publication
Date de publication:
15 Feb 2020
15 Feb 2020
Historique:
received:
28
06
2019
revised:
17
10
2019
accepted:
25
11
2019
pubmed:
1
12
2019
medline:
18
11
2020
entrez:
1
12
2019
Statut:
ppublish
Résumé
The article describes the preparation and characterization of 3D-printed tablets with bicalutamide obtained using two-material co-extrusion-based fused deposition modeling (FDM). This method is a modification of typical two-material FDM where separate nozzles are used to print from two filaments. In this work we used a ZMorph® 3D printer with DualPro printhead which allows us to co-extrude two filaments through a single nozzle. This approach gives the opportunity to modify tablet properties in a wide range, especially the dissolution rate, by producing dosage forms with a complex design. The great advantage of this method is that switching between immediate dosage form and controlled release does not require any change in the 3D-printer set-up. We checked the accuracy of co-extrusion printing simply by weighing the amounts of soluble and insoluble material in the printed object as well as calculating the volumes of the printed objects from micro computed tomography (µ-CT) images. We printed several tablets with a different design including simple one-material tablets, two- and three-compartment tablets with various internal structure and composition of the printing path. The dissolution tests were conducted in sink and non-sink conditions. We obtained tablets with desired bicalutamide dissolution profiles, i.e. immediate, controlled, and combined. The formation of spatial matrix slows down the dissolution in controlled and combined release bicalutamide tablets what was confirmed by µ-CT analysis before and after dissolution.
Identifiants
pubmed: 31785383
pii: S0928-0987(19)30442-7
doi: 10.1016/j.ejps.2019.105169
pii:
doi:
Substances chimiques
Anilides
0
Antineoplastic Agents
0
Nitriles
0
Tablets
0
Tosyl Compounds
0
bicalutamide
A0Z3NAU9DP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105169Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.